BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.
FDA Action Alert: Blueprint, Liquidia, Revance, Rhythm and Merck
Blockbusters, Checkpoint Inhibitors, Clinical Trials, FDA, Frown Lines, LEPR deficiency obesity, LEPR deficiency obesity, Metastatic Rearranged During Transfection (RET) Fusion-Positive Non-Small Cell Lung Cancer (NSCLC), New Drug Applications, New Drug Approvals, Non-Small Cell Lung Cancer, Patent Lawsuits, PD-1/PD-L1 inhibitors, PDUFA, Priority Review Status, Pro-Opiomelanocortin (POMC) Deficiency Obesity, Pulmonary Arterial Hypertension, R&D, Therapeutics, Triple Negative Breast Cancer (TNBC)The U.S. Food and Drug Administration’s PDUFA dates for the last week of November 2020 include a review of Liquidia Technologies’ NDA for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-approved test.
Roche company Genentech presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Immunomedics drug Trodelvy extends survival in breast cancer patients
Accelerated Approval, Antibody-Drug Conjugates (ADCs), Boxed Warning, Business, Cancer Cells, Clinical Trials, Deals, European Society for Medical Oncology (ESMO), FDA, Metastatic Triple-Negative Breast Cancer (mTNBC), R&D, TherapeuticsImmunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.
Merck and Seattle Genetics Ink Two New Strategic Cancer Collaborations
Antibody-Drug Conjugates (ADCs), Blockbusters, Business, Cancer, Checkpoint Inhibitors, Clinical Trials, Collaborations, Deals, HER2 protein, Investments, Licensing, Oncology, Premarket Trading, R&D, Small Molecules, Solid Tumors, Triple Negative Breast Cancer (TNBC), Tyrosine kinase inhibitorsSeattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.
Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
Immunomedics announced that the company’s Phase III study involving Trodelvy met the primary endpoint of progression-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.